Date:	October 1 2021	
Your Name:_	Sheng Liu	
_	Manuscript Title:_Comparing the efficacy and safety of the Skyflow	device with
the	nose of Solitaire FR stent in patients with acute ischemic stroke: A pro-	ospective,
	ulticenter, randomized, non-inferiority clinical trial	

Manuscript number (if known):______neurintsurg-2021-017765.R1__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3 Royalties or licenses
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Interpretation production producting producting producting production producting producting productin
Interpretation production producting producting producting production producting producting productin
Interpretation production producting producting producting production producting producting productin
manuscript writing or educational events
educational events None 6 Payment for expert testimony None 7 Support for attending meetings and/or travel None 7 Support for attending meetings and/or travel None 8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
testimony
Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and for attending meeting meeting meetings and for atte
meetings and/or travel
meetings and/or travel
8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
pending
pending
Safety Monitoring Board or
Safety Monitoring Board or
Safety Monitoring Board or
Advisory Board
10 Leadership or fiduciary role None in other board, society,
committee or advocacy
group, paid or unpaid
11 Stock or stock options None
12 Receipt of equipment, materials, drugs, medical None
writing, gifts or other
services
13 Other financial or non- financial interests None

Date:	October 1 2021	
Your Name:_	Shouchun Wang	
	Manuscript Title:_Comparing the efficacy and safety of the Skyflow device with	
the	ose of Solitaire FR stent in patients with acute ischemic stroke: A prospective,	
mu	llticenter, randomized, non-inferiority clinical trial	

Manuscript number (if known):______neurintsurg-2021-017765.R1__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3 Royalties or licenses
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Interpretation production producting producting producting production producting producting productin
Interpretation production producting producting producting production producting producting productin
Interpretation production producting producting producting production producting producting productin
manuscript writing or educational events
educational events None 6 Payment for expert testimony None 7 Support for attending meetings and/or travel None 7 Support for attending meetings and/or travel None 8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
testimony
Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and for attending meeting meeting meetings and for atte
meetings and/or travel
meetings and/or travel
8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
pending
pending
Safety Monitoring Board or
Safety Monitoring Board or
Safety Monitoring Board or
Advisory Board
10 Leadership or fiduciary role None in other board, society,
committee or advocacy
group, paid or unpaid
11 Stock or stock options None
12 Receipt of equipment, materials, drugs, medical None
writing, gifts or other
services
13 Other financial or non- financial interests None

Date:	October 1 2021	
Your Name:	Changming Wen	
	Manuscript Title:_Comparing the efficacy and safety of the Skyflow device with	
th	ose of Solitaire FR stent in patients with acute ischemic stroke: A prospective,	
m	ulticenter, randomized, non-inferiority clinical trial	

Manuscript number (if known):______neurintsurg-2021-017765.R1__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial	planning of the work
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
	Time frame: past	36 months
Grants or contracts from any entity (if not indicated in item #1 above).	None	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated

3 Royalties or licenses
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Interpretation production producting producting producting production producting producting productin
Interpretation production producting producting producting production producting producting productin
Interpretation production producting producting producting production producting producting productin
manuscript writing or educational events
educational events None 6 Payment for expert testimony None 7 Support for attending meetings and/or travel None 7 Support for attending meetings and/or travel None 8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
testimony
Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and for attending meeting meeting meetings and for atte
meetings and/or travel
meetings and/or travel
8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
pending
pending
Safety Monitoring Board or
Safety Monitoring Board or
Safety Monitoring Board or
Advisory Board
10 Leadership or fiduciary role None in other board, society,
committee or advocacy
group, paid or unpaid
11 Stock or stock options None
12 Receipt of equipment, materials, drugs, medical None
writing, gifts or other
services
13 Other financial or non- financial interests None

Date:	October 1 2021
Your Name:	Guangxian Nan
	Manuscript Title:_Comparing the efficacy and safety of the Skyflow device with
tho	se of Solitaire FR stent in patients with acute ischemic stroke: A prospective,
mu	lticenter, randomized, non-inferiority clinical trial

Manuscript number (if known):______neurintsurg-2021-017765.R1__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial	planning of the work
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
	Time frame: past	36 months
Grants or contracts from any entity (if not indicated in item #1 above).	None	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated

3 Royalties or licenses
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Interpretation production producting producting producting production producting producting productin
Interpretation production producting producting producting production producting producting productin
Interpretation production producting producting producting production producting producting productin
manuscript writing or educational events
educational events None 6 Payment for expert testimony None 7 Support for attending meetings and/or travel None 7 Support for attending meetings and/or travel None 8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
testimony
Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and for attending meeting meeting meetings and for atte
meetings and/or travel
meetings and/or travel
8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
pending
pending
Safety Monitoring Board or
Safety Monitoring Board or
Safety Monitoring Board or
Advisory Board
10 Leadership or fiduciary role None in other board, society,
committee or advocacy
group, paid or unpaid
11 Stock or stock options None
12 Receipt of equipment, materials, drugs, medical None
writing, gifts or other
services
13 Other financial or non- financial interests None

Date:	October 1 2021 _	
Your Name:_	Haitao Guan	
_	Manuscript Title:_Comparing the	efficacy and safety of the Skyflow device with
the	ose of Solitaire FR stent in patient	s with acute ischemic stroke: A prospective,
mı	ılticenter, randomized, non-inferi	ority clinical trial

Manuscript number (if known):______neurintsurg-2021-017765.R1__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial	planning of the work
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
	Time frame: past	36 months
Grants or contracts from any entity (if not indicated in item #1 above).	None	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated

3 Royalties or licenses
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Interpretation production producting producting producting production producting producting productin
Interpretation production producting producting producting production producting producting productin
Interpretation production producting producting producting production producting producting productin
manuscript writing or educational events
educational events None 6 Payment for expert testimony None 7 Support for attending meetings and/or travel None 7 Support for attending meetings and/or travel None 8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
testimony
Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and for attending meeting meeting meetings and for atte
meetings and/or travel
meetings and/or travel
8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
pending
pending
Safety Monitoring Board or
Safety Monitoring Board or
Safety Monitoring Board or
Advisory Board
10 Leadership or fiduciary role None in other board, society,
committee or advocacy
group, paid or unpaid
11 Stock or stock options None
12 Receipt of equipment, materials, drugs, medical None
writing, gifts or other
services
13 Other financial or non- financial interests None

Date:	October 1 2021	
Your Name:_	Hongyu Qiao	
	Manuscript Title:_Comparing the	efficacy and safety of the Skyflow device with
the	ose of Solitaire FR stent in patient	s with acute ischemic stroke: A prospective,
	ılticenter, randomized, non-inferi	ority clinical trial

Manuscript number (if known):______neurintsurg-2021-017765.R1__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3 Royalties or licenses
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Interpretation production producting producting producting production producting producting productin
Interpretation production producting producting producting production producting producting productin
Interpretation production producting producting producting production producting producting productin
manuscript writing or educational events
educational events None 6 Payment for expert testimony None 7 Support for attending meetings and/or travel None 7 Support for attending meetings and/or travel None 8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
testimony
Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and for attending meeting meeting meetings and for atte
meetings and/or travel
meetings and/or travel
8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
pending
pending
Safety Monitoring Board or
Safety Monitoring Board or
Safety Monitoring Board or
Advisory Board
10 Leadership or fiduciary role None in other board, society,
committee or advocacy
group, paid or unpaid
11 Stock or stock options None
12 Receipt of equipment, materials, drugs, medical None
writing, gifts or other
services
13 Other financial or non- financial interests None

Date:	October 1 2021	
Your Name:	Hongzhuang Li	
	Manuscript Title:_Comparing the efficacy and safety of the Skyflow device with	
th	ose of Solitaire FR stent in patients with acute ischemic stroke: A prospective,	
m	ulticenter, randomized, non-inferiority clinical trial	

Manuscript number (if known):______neurintsurg-2021-017765.R1__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3 Royalties or licenses
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Interpretation production producting producting producting production producting producting productin
Interpretation production producting producting producting production producting producting productin
Interpretation production producting producting producting production producting producting productin
manuscript writing or educational events
educational events None 6 Payment for expert testimony None 7 Support for attending meetings and/or travel None 7 Support for attending meetings and/or travel None 8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
testimony
Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and for attending meeting meeting meetings and for atte
meetings and/or travel
meetings and/or travel
8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
pending
pending
Safety Monitoring Board or
Safety Monitoring Board or
Safety Monitoring Board or
Advisory Board
10 Leadership or fiduciary role None in other board, society,
committee or advocacy
group, paid or unpaid
11 Stock or stock options None
12 Receipt of equipment, materials, drugs, medical None
writing, gifts or other
services
13 Other financial or non- financial interests None

Date:	October 1 2021
Your Name:_	Jianfeng Han
	Manuscript Title:_Comparing the efficacy and safety of the Skyflow device with
th	ose of Solitaire FR stent in patients with acute ischemic stroke: A prospective,
un	use of solitane i R stelle in parents with acute ischeline subket is prospective,

Manuscript number (if known):______neurintsurg-2021-017765.R1__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3 Royalties or licenses
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Interstant Sector Interstant Sector Interstant Sector Interstant Sector Interstant Interstant Sector
Interstant Sector Interstant Sector Interstant Sector Interstant Sector Interstant Interstant Sector
Interstant Sector Interstant Sector Interstant Sector Interstant Sector Interstant Interstant Sector
manuscript writing or educational events
educational events None 6 Payment for expert testimony None 7 Support for attending meetings and/or travel None 7 Support for attending meetings and/or travel None 8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
testimony
Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and for attending meeting meeting meetings and for atte
meetings and/or travel
meetings and/or travel
8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
pending
pending
Safety Monitoring Board or
Safety Monitoring Board or
Safety Monitoring Board or
Advisory Board
10 Leadership or fiduciary role None in other board, society,
committee or advocacy
group, paid or unpaid
11 Stock or stock options None
12 Receipt of equipment, materials, drugs, medical None
writing, gifts or other
services
13 Other financial or non- financial interests None

Date:	October 1 2021			
Your Name:	Jianping Gu			
_	Manuscript Title:_Comparing the eff	ficacy and safety of the Skyflow device with		
th	ose of Solitaire FR stent in patients w	vith acute ischemic stroke: A prospective,		
mu	nulticenter, randomized, non-inferiority clinical trial			

Manuscript number (if known):______neurintsurg-2021-017765.R1__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3 Royalties or licenses				
Support for attending meetings and/or travel	3	Royalties or licenses	None	
Support for attending meetings and/or travel				
Support for attending meetings and/or travel				
Interpretation production producting producting producting production producting producting productin	4	Consulting fees	None	
Interpretation production producting producting producting production producting producting productin				
Interpretation production producting producting producting production producting producting productin				
manuscript writing or educational events	5	lectures, presentations,	None	
educational events None 6 Payment for expert testimony None 7 Support for attending meetings and/or travel None 7 Support for attending meetings and/or travel None 8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None				
testimony				
Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and for attending meeting meeting meetings and for atte	6		None	
meetings and/or travel				
meetings and/or travel	L			
8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None	7	Support for attending meetings and/or travel	None	
pending				
pending				
Safety Monitoring Board or	8		None	
Safety Monitoring Board or				
Safety Monitoring Board or				
	9	Safety Monitoring Board or	None	
Advisory Board		Advisory Board		
10 Leadership or fiduciary role None in other board, society,	10	in other board, society,	None	
committee or advocacy				
group, paid or unpaid				
11 Stock or stock options None	11	Stock or stock options	None	
12 Receipt of equipment, materials, drugs, medical None	12	materials, drugs, medical	None	
writing, gifts or other				
services				
13 Other financial or non- financial interests None	13		None	

Date:	October 1 2021			
Your Name:_	Jinchao Liu			
	Manuscript Title:_Comparing the efficacy and safety of the Skyflow device with	h		
the	ose of Solitaire FR stent in patients with acute ischemic stroke: A prospective,			
	nulticenter, randomized, non-inferiority clinical trial			

Manuscript number (if known):______neurintsurg-2021-017765.R1__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3 Royalties or licenses				
Support for attending meetings and/or travel	3	Royalties or licenses	None	
Support for attending meetings and/or travel				
Support for attending meetings and/or travel				
Interpretation production producting producting producting production producting producting productin	4	Consulting fees	None	
Interpretation production producting producting producting production producting producting productin				
Interpretation production producting producting producting production producting producting productin				
manuscript writing or educational events	5	lectures, presentations,	None	
educational events None 6 Payment for expert testimony None 7 Support for attending meetings and/or travel None 7 Support for attending meetings and/or travel None 8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None				
testimony				
Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and for attending meeting meeting meetings and for atte	6		None	
meetings and/or travel				
meetings and/or travel	L			
8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None	7	Support for attending meetings and/or travel	None	
pending				
pending				
Safety Monitoring Board or	8		None	
Safety Monitoring Board or				
Safety Monitoring Board or				
	9	Safety Monitoring Board or	None	
Advisory Board		Advisory Board		
10 Leadership or fiduciary role None in other board, society,	10	in other board, society,	None	
committee or advocacy				
group, paid or unpaid				
11 Stock or stock options None	11	Stock or stock options	None	
12 Receipt of equipment, materials, drugs, medical None	12	materials, drugs, medical	None	
writing, gifts or other				
services				
13 Other financial or non- financial interests None	13		None	

 Date:
 _____October 1 2021

 Your Name:
 Liangfu Zhu

 Manuscript Title:_Comparing the efficacy and safety of the Skyflow device with

 those of Solitaire FR stent in patients with acute ischemic stroke: A prospective,

 multicenter, randomized, non-inferiority clinical trial

Manuscript number (if known):______neurintsurg-2021-017765.R1__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	None	
	in item #1 above).		

3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
0		Nexa	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical	None	
1	writing, gifts or other		
	services		
13	Other financial or non- financial interests	None	

Date:	October 1 2021		
Your Name:_	Liping Wei		
	Manuscript Title:_Comparing the efficacy and safety of the Skyflow device with		
the	ose of Solitaire FR stent in patients with acute ischemic stroke: A prospective,		

Manuscript number (if known):______neurintsurg-2021-017765.R1__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial	planning of the work
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
	Time frame: past	36 months
Grants or contracts from any entity (if not indicated in item #1 above).	None	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated

3 Royalties or licenses				
Support for attending meetings and/or travel	3	Royalties or licenses	None	
Support for attending meetings and/or travel				
Support for attending meetings and/or travel				
Interstant interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant	4	Consulting fees	None	
Interstant interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant				
Interstant interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant Interstant				
manuscript writing or educational events	5	lectures, presentations,	None	
educational events None 6 Payment for expert testimony None 7 Support for attending meetings and/or travel None 7 Support for attending meetings and/or travel None 8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None				
testimony				
Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and for attending meeting meeting meetings and for atte	6		None	
meetings and/or travel				
meetings and/or travel	L			
8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None	7	Support for attending meetings and/or travel	None	
pending				
pending				
Safety Monitoring Board or	8		None	
Safety Monitoring Board or				
Safety Monitoring Board or				
	9	Safety Monitoring Board or	None	
Advisory Board		Advisory Board		
10 Leadership or fiduciary role None in other board, society,	10	in other board, society,	None	
committee or advocacy				
group, paid or unpaid				
11 Stock or stock options None	11	Stock or stock options	None	
12 Receipt of equipment, materials, drugs, medical None	12	materials, drugs, medical	None	
writing, gifts or other				
services				
13 Other financial or non- financial interests None	13		None	

Date:	October 1 2021
Your Name:_	Qiang Li
	Manuscript Title:_Comparing the efficacy and safety of the Skyflow device with
the	se of Solitaire FR stent in patients with acute ischemic stroke: A prospective,
	lticenter, randomized, non-inferiority clinical trial

Manuscript number (if known):______neurintsurg-2021-017765.R1__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3 Royalties or licenses
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Interpretation production producting producting producting production producting producting productin
Interpretation production producting producting producting production producting producting productin
Interpretation production producting producting producting production producting producting productin
manuscript writing or educational events
educational events None 6 Payment for expert testimony None 7 Support for attending meetings and/or travel None 7 Support for attending meetings and/or travel None 8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
testimony
Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and for attending meeting meeting meetings and for atte
meetings and/or travel
meetings and/or travel
8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
pending
pending
Safety Monitoring Board or
Safety Monitoring Board or
Safety Monitoring Board or
Advisory Board
10 Leadership or fiduciary role None in other board, society,
committee or advocacy
group, paid or unpaid
11 Stock or stock options None
12 Receipt of equipment, materials, drugs, medical None
writing, gifts or other
services
13 Other financial or non- financial interests None

October 1 2021
Tengfei Zhou
Manuscript Title:_Comparing the efficacy and safety of the Skyflow device with
e of Solitaire FR stent in patients with acute ischemic stroke: A prospective,
ticenter, randomized, non-inferiority clinical trial
•

Manuscript number (if known):______neurintsurg-2021-017765.R1__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial	planning of the work
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
	Time frame: past	36 months
Grants or contracts from any entity (if not indicated in item #1 above).	None	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated

3 Royalties or licenses
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Interpretation production producting producting producting production producting producting productin
Interpretation production producting producting producting production producting producting productin
Interpretation production producting producting producting production producting producting productin
manuscript writing or educational events
educational events None 6 Payment for expert testimony None 7 Support for attending meetings and/or travel None 7 Support for attending meetings and/or travel None 8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
testimony
Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and for attending meeting meeting meetings and for atte
meetings and/or travel
meetings and/or travel
8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
pending
pending
Safety Monitoring Board or
Safety Monitoring Board or
Safety Monitoring Board or
Advisory Board
10 Leadership or fiduciary role None in other board, society,
committee or advocacy
group, paid or unpaid
11 Stock or stock options None
12 Receipt of equipment, materials, drugs, medical None
writing, gifts or other
services
13 Other financial or non- financial interests None

Date:	October 1 2021	
Your Name:_	Tianxiao Li	
	Manuscript Title:_Comparing the efficacy and safety of the Skyflow device	with
the	ose of Solitaire FR stent in patients with acute ischemic stroke: A prospectiv	ve,
	ulticenter, randomized, non-inferiority clinical trial	

Manuscript number (if known):______neurintsurg-2021-017765.R1__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3 Royalties or licenses
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Interpretation production producting producting producting production producting producting productin
Interpretation production producting producting producting production producting producting productin
Interpretation production producting producting producting production producting producting productin
manuscript writing or educational events
educational events None 6 Payment for expert testimony None 7 Support for attending meetings and/or travel None 7 Support for attending meetings and/or travel None 8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
testimony
Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and for attending meeting meeting meetings and for atte
meetings and/or travel
meetings and/or travel
8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
pending
pending
Safety Monitoring Board or
Safety Monitoring Board or
Safety Monitoring Board or
Advisory Board
10 Leadership or fiduciary role None in other board, society,
committee or advocacy
group, paid or unpaid
11 Stock or stock options None
12 Receipt of equipment, materials, drugs, medical None
writing, gifts or other
services
13 Other financial or non- financial interests None

Date:	October 1 2021	
Your Name:_	Weixing Bai	
	Manuscript Title:_Comparing the efficacy and	safety of the Skyflow device with
the	ose of Solitaire FR stent in patients with acute	ischemic stroke: A prospective,
mu	lticenter, randomized, non-inferiority clinical	l trial

Manuscript number (if known):______neurintsurg-2021-017765.R1__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3 Royalties or licenses
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Iectures, presentations, speakers bureaus, manuscript writing or educational events
Iectures, presentations, speakers bureaus, manuscript writing or educational events
Iectures, presentations, speakers bureaus, manuscript writing or educational events
manuscript writing or educational events
educational events None 6 Payment for expert testimony None 7 Support for attending meetings and/or travel None 7 Support for attending meetings and/or travel None 8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
testimony
Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and for attending meeting meeting meetings and for atte
meetings and/or travel
meetings and/or travel
8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
pending
pending
Safety Monitoring Board or
Safety Monitoring Board or
Safety Monitoring Board or
Advisory Board
10 Leadership or fiduciary role None in other board, society,
committee or advocacy
group, paid or unpaid
11 Stock or stock options None
12 Receipt of equipment, materials, drugs, medical None
writing, gifts or other
services
13 Other financial or non- financial interests None

Date:	October 1 2021
Your Name:_	Xiao Liu
	Manuscript Title:_Comparing the efficacy and safety of the Skyflow device with
the	ose of Solitaire FR stent in patients with acute ischemic stroke: A prospective,
	llticenter, randomized, non-inferiority clinical trial

Manuscript number (if known):______neurintsurg-2021-017765.R1__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3 Royalties or licenses
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Iectures, presentations, speakers bureaus, manuscript writing or educational events
Iectures, presentations, speakers bureaus, manuscript writing or educational events
Iectures, presentations, speakers bureaus, manuscript writing or educational events
manuscript writing or educational events
educational events None 6 Payment for expert testimony None 7 Support for attending meetings and/or travel None 7 Support for attending meetings and/or travel None 8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
testimony
Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and for attending meeting meeting meetings and for atte
meetings and/or travel
meetings and/or travel
8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
pending
pending
Safety Monitoring Board or
Safety Monitoring Board or
Safety Monitoring Board or
Advisory Board
10 Leadership or fiduciary role None in other board, society,
committee or advocacy
group, paid or unpaid
11 Stock or stock options None
12 Receipt of equipment, materials, drugs, medical None
writing, gifts or other
services
13 Other financial or non- financial interests None

Date:	October 1 2021
Your Name:	Xueli Cai
_	Manuscript Title:_Comparing the efficacy and safety of the Skyflow device with
the	ose of Solitaire FR stent in patients with acute ischemic stroke: A prospective,

Manuscript number (if known):______neurintsurg-2021-017765.R1__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3 Royalties or licenses
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Iectures, presentations, speakers bureaus, manuscript writing or educational events
Iectures, presentations, speakers bureaus, manuscript writing or educational events
Interpretation production producting producting producting production producting producting productin
manuscript writing or educational events
educational events None 6 Payment for expert testimony None 7 Support for attending meetings and/or travel None 7 Support for attending meetings and/or travel None 8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
testimony
Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and for attending meeting meeting meetings and for atte
meetings and/or travel
meetings and/or travel
8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
pending
pending
Safety Monitoring Board or
Safety Monitoring Board or
Safety Monitoring Board or
Advisory Board
10 Leadership or fiduciary role None in other board, society,
committee or advocacy
group, paid or unpaid
11 Stock or stock options None
12 Receipt of equipment, materials, drugs, medical None
writing, gifts or other
services
13 Other financial or non- financial interests None

Date:	October 1 2021	
Your Name:_	Yingkun He	
	Manuscript Title:_Comparing the	efficacy and safety of the Skyflow device with
the	ose of Solitaire FR stent in patient	s with acute ischemic stroke: A prospective,
mu	ılticenter, randomized, non-inferi	ority clinical trial
mu	ılticenter, randomized, non-inferi	ority clinical trial

Manuscript number (if known):______neurintsurg-2021-017765.R1__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3 Royalties or licenses
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Interpretation production producting producting producting production producting producting productin
Interpretation production producting producting producting production producting producting productin
Interpretation production producting producting producting production producting producting productin
manuscript writing or educational events
educational events None 6 Payment for expert testimony None 7 Support for attending meetings and/or travel None 7 Support for attending meetings and/or travel None 8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
testimony
Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and for attending meeting meeting meetings and for atte
meetings and/or travel
meetings and/or travel
8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
pending
pending
Safety Monitoring Board or
Safety Monitoring Board or
Safety Monitoring Board or
Advisory Board
10 Leadership or fiduciary role None in other board, society,
committee or advocacy
group, paid or unpaid
11 Stock or stock options None
12 Receipt of equipment, materials, drugs, medical None
writing, gifts or other
services
13 Other financial or non- financial interests None

Date:	October 1 2021	
Your Name:_	Youming Long	
	Manuscript Title:_Comparing the efficacy and safety of the Skyflow device with	
the	ose of Solitaire FR stent in patients with acute ischemic stroke: A prospective,	
mu	ulticenter, randomized, non-inferiority clinical trial	

Manuscript number (if known):______neurintsurg-2021-017765.R1__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3 Royalties or licenses
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Support for attending meetings and/or travel
Iectures, presentations, speakers bureaus, manuscript writing or educational events
Iectures, presentations, speakers bureaus, manuscript writing or educational events
Interpretation production producting producting producting production producting producting productin
manuscript writing or educational events
educational events None 6 Payment for expert testimony None 7 Support for attending meetings and/or travel None 7 Support for attending meetings and/or travel None 8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
testimony
Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and/or travel Image: Support for attending meetings and for attending meeting meeting meetings and for atte
meetings and/or travel
meetings and/or travel
8 Patents planned, issued or pending None 9 Participation on a Data Safety Monitoring Board or None
pending
pending
Safety Monitoring Board or
Safety Monitoring Board or
Safety Monitoring Board or
Advisory Board
10 Leadership or fiduciary role None in other board, society,
committee or advocacy
group, paid or unpaid
11 Stock or stock options None
12 Receipt of equipment, materials, drugs, medical None
writing, gifts or other
services
13 Other financial or non- financial interests None

Date:	October 1 2021
Your Name:_	Yude Zhang
	Manuscript Title:_Comparing the efficacy and safety of the Skyflow device with
the	ose of Solitaire FR stent in patients with acute ischemic stroke: A prospective,
	ulticenter, randomized, non-inferiority clinical trial

Manuscript number (if known):______neurintsurg-2021-017765.R1__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3 Royalties or licenses				
Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	3	Royalties or licenses	None	
Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events				
5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events				
lectures, presentations, speakers bureaus, manuscript writing or educational events	4	Consulting fees	None	
lectures, presentations, speakers bureaus, manuscript writing or educational events				
lectures, presentations, speakers bureaus, manuscript writing or educational events				
manuscript writing or educational events	5	lectures, presentations,	None	
educational events None 6 Payment for expert testimony None 7 Support for attending meetings and/or travel meetings and/or travel None 7 Support for attending meetings and/or travel None 8 Patents planned, issued or pending None 9 Patticipation on a Data Safety Monitoring Board or Advisory Board None 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid None 11 Stock or stock options None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services None 13 Other financial or non- None				
testimony		educational events		
meetings and/or travel include include include include include 8 Patents planned, issued or pending	6		None	
meetings and/or travel include include include include include 8 Patents planned, issued or pending				
meetings and/or travel include include include include include 8 Patents planned, issued or pending				
pending	7		None	
pending				
pending				
Safety Monitoring Board or Advisory Board Image: Complexity of Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Image: Complexity of Advisory Board 11 Stock or stock options Image: Complexity of Advisory Board 11 Stock or stock options Image: Complexity of Advisory Board 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services None 13 Other financial or non- Image: None	8	-	None	
Safety Monitoring Board or Advisory Board Image: Complexity of Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Image: Complexity of Advisory Board 11 Stock or stock options Image: Complexity of Advisory Board 11 Stock or stock options Image: Complexity of Advisory Board 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services None 13 Other financial or non- Image: None				
Safety Monitoring Board or Advisory Board Image: Comparison of Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Board or in other board, society, in other board, society, in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Board or in other board, society, in other board, so	-		•	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	9	Safety Monitoring Board or	None	
in other board, society, committee or advocacy group, paid or unpaid		Advisory Board		
in other board, society, committee or advocacy group, paid or unpaid				
group, paid or unpaid	10	in other board, society,	None	
11 Stock or stock options None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services None 13 Other financial or non- None				
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services				
materials, drugs, medical writing, gifts or other services	11	Stock or stock options	None	
materials, drugs, medical writing, gifts or other services				
materials, drugs, medical writing, gifts or other services				
services None None	12	materials, drugs, medical	None	
13 Other financial or non None				
	13		None	

Date:	October 1 2021
Your Name:_	Zhaoshuo Li
	Manuscript Title:_Comparing the efficacy and safety of the Skyflow device with
the	ose of Solitaire FR stent in patients with acute ischemic stroke: A prospective,
	llticenter, randomized, non-inferiority clinical trial

Manuscript number (if known):______neurintsurg-2021-017765.R1__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3 Royalties or licenses				
Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	3	Royalties or licenses	None	
Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events				
5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events				
lectures, presentations, speakers bureaus, manuscript writing or educational events	4	Consulting fees	None	
lectures, presentations, speakers bureaus, manuscript writing or educational events				
lectures, presentations, speakers bureaus, manuscript writing or educational events				
manuscript writing or educational events	5	lectures, presentations,	None	
educational events None 6 Payment for expert testimony None 7 Support for attending meetings and/or travel meetings and/or travel None 7 Support for attending meetings and/or travel None 8 Patents planned, issued or pending None 9 Patticipation on a Data Safety Monitoring Board or Advisory Board None 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid None 11 Stock or stock options None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services None 13 Other financial or non- None				
testimony		educational events		
meetings and/or travel include include include include include 8 Patents planned, issued or pending	6		None	
meetings and/or travel include include include include include 8 Patents planned, issued or pending				
meetings and/or travel include include include include include 8 Patents planned, issued or pending				
pending	7		None	
pending				
pending				
Safety Monitoring Board or Advisory Board Image: Complexity of Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Image: Complexity of Advisory Board 11 Stock or stock options Image: Complexity of Advisory Board 11 Stock or stock options Image: Complexity of Advisory Board 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services None 13 Other financial or non- Image: None	8	-	None	
Safety Monitoring Board or Advisory Board Image: Complexity of Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Image: Complexity of Advisory Board 11 Stock or stock options Image: Complexity of Advisory Board 11 Stock or stock options Image: Complexity of Advisory Board 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services None 13 Other financial or non- Image: None				
Safety Monitoring Board or Advisory Board Image: Comparison of Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Board or in other board, society, in other board, society, in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Board or in other board, society, in other board, so	-		•	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	9	Safety Monitoring Board or	None	
in other board, society, committee or advocacy group, paid or unpaid		Advisory Board		
in other board, society, committee or advocacy group, paid or unpaid				
group, paid or unpaid	10	in other board, society,	None	
11 Stock or stock options None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services None 13 Other financial or non- None				
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services				
materials, drugs, medical writing, gifts or other services	11	Stock or stock options	None	
materials, drugs, medical writing, gifts or other services				
materials, drugs, medical writing, gifts or other services				
services None None	12	materials, drugs, medical	None	
13 Other financial or non None				
	13		None	

Date:	October 1 2021
Your Name:_	Zhenxin Zhao
	Manuscript Title:_Comparing the efficacy and safety of the Skyflow device with
the	ose of Solitaire FR stent in patients with acute ischemic stroke: A prospective,
m	llticenter, randomized, non-inferiority clinical trial

Manuscript number (if known):______neurintsurg-2021-017765.R1__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3 Royalties or licenses				
Second	3	Royalties or licenses	None	
Second				
S Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events				
lectures, presentations, speakers bureaus, manuscript writing or educational events	4	Consulting fees	None	
lectures, presentations, speakers bureaus, manuscript writing or educational events				
lectures, presentations, speakers bureaus, manuscript writing or educational events				
manuscript writing or educational events	5	lectures, presentations,	None	
educational events				
testimony		educational events		
meetings and/or travel include include include include include 8 Patents planned, issued or pending include include 9 Participation on a Data Safety Monitoring Board or Advisory Board include include 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid include include 11 Stock or stock options include include include 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services include include 13 Other financial or non- include include include	6		None	
meetings and/or travel include include include include include 8 Patents planned, issued or pending include include 9 Participation on a Data Safety Monitoring Board or Advisory Board include include 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid include include 11 Stock or stock options include include include 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services include include 13 Other financial or non- include include include				
meetings and/or travel include include include include include 8 Patents planned, issued or pending include include 9 Participation on a Data Safety Monitoring Board or Advisory Board include include 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid include include 11 Stock or stock options include include include 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services include include 13 Other financial or non- include include include				
pending	7		None	
pending				
pending				
Safety Monitoring Board or Advisory Board Image: Comparison of Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Board or in other board, society, in other board, society, in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Board or in other board, society, in other board, so	8	-	None	
Safety Monitoring Board or Advisory Board Image: Comparison of Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Board or in other board, society, in other board, society, in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Board or in other board, society, in other board, so				
Safety Monitoring Board or Advisory Board Image: Comparison of Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Monitoring Board or in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Board or in other board, society, in other board, society, in other board, society, committee or advocacy group, paid or unpaid Image: Comparison of Board or in other board, society, in other board, so	-		•	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	9	Safety Monitoring Board or	None	
in other board, society, committee or advocacy group, paid or unpaid		Advisory Board		
in other board, society, committee or advocacy group, paid or unpaid				
group, paid or unpaid	10	in other board, society,	None	
11 Stock or stock options None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services None 13 Other financial or non- None				
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services				
materials, drugs, medical writing, gifts or other services	11	Stock or stock options	None	
materials, drugs, medical writing, gifts or other services				
materials, drugs, medical writing, gifts or other services				
services Image: Services 13 Other financial or non- None	12	materials, drugs, medical	None	
13 Other financial or non None				
	13		None	